Previous close | 0.2500 |
Open | N/A |
Bid | 0.0500 |
Ask | 0.5500 |
Strike | 12.50 |
Expiry date | 2024-07-19 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 2 |
Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensingCAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the election of Richard N. Kender to its Board of Directors following its annual meeting of stockholders. Mr. Kender’s industry knowledge a
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fireside chats at two upcoming investor conferences. Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 9:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare ConferenceDate: Monday, June 10, 2024Tim